Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare thalidomide + dexamethasone with bortezomib +
dexamethasone in patients with multiple myeloma refractory to melphalan therapy. The main
goal is to find out which of these two 2:nd line regimens that offers the patients the best
chance for a response with as long duration and as good quality of life as possible.